Prerpints.org logo
Preprint
Review

Platelet-Rich Plasma Power Mix gel (ppm) - An Orthobiologic Optimization Protocol Rich in Growth Factors and Fibrin

Altmetrics

Downloads

136

Views

58

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

06 June 2023

Posted:

07 June 2023

You are already at the latest version

Alerts
Abstract
Platelet and fibrin-rich orthobiologic products, such as autologous platelet concentrates, have been extensively studied and appreciated for their beneficial effects in multiple conditions. PRP and its derivatives, including PRF, have demonstrated encouraging outcomes in clinical and laboratory settings, particularly in the treatment of musculoskeletal disorders such as OA. Although PRP and PRF have distinct characteristics, they share similar properties. The relative abundance of platelets, peripheral blood cells and molecular components in these orthobiologic products stimulate numerous biological pathways. These include inflammatory modulation, augmented neovascularization, and delivery of pro-anabolic stimuli that regulate cell recruitment, proliferation, and differentiation. Furthermore, the fibrinolytic system, which is sometimes overlooked, plays a crucial role in musculoskeletal regenerative medicine by regulating proteolytic activity and promoting the recruitment of inflammatory cells and MSCs in areas of tissue regeneration, such as bone, cartilage, and muscle. PRP acts as a potent signaling agent; however, it diffuses easily, while the fibrin from PRF offers a durable scaffolding effect that promotes cell activity. The combination of fibrin with hyaluronic acid, another well-studied orthobiologic product, has been shown to improve its scaffolding properties, leading to more robust fibrin polymerization. This supports cell survival, attachment, migration, and proliferation. Therefore, the administration of the "power mix" containing HA and autologous PRP + PRF may prove to be a safe and cost-effective approach in regenerative medicine.
Keywords: 
Subject: Biology and Life Sciences  -   Biology and Biotechnology

1. Introduction

Osteoarthritis (OA) is acknowledged as a major degenerative and progressive joint disease responsible for significant pain and disability in the adult population [1]. The incidence of OA around the globe has risen significantly in the last few decades due to the aging of the population and poor metabolic health status [2,3,4]. This disease can be often challenging to treat as it presents a multifactorial nature, being mainly characterized by the physiological and architectural changes in the joint compartment as a whole [5]. It is highly influenced by the interplay between innate and extraneous factors, consequently dictating disease progression and the patients’ response to treatments [6]. The most common features of OA (Table 1) include progressive loss of articular cartilage, osteophyte formation, thickening of the subchondral bone, escalated synovial inflammation, ligaments and meniscal degeneration and overall joint hypertrophy [3].
Multiple treatment strategies have been listed in the literature, however, these are largely subdivided into pharmacological and non-pharmacological alternatives to avoid surgical intervention [5]. Since OA symptoms are known to be intense, physicians may often prescribe patients a combination of drugs at different stages of the disease, aiming to block inflammatory nociceptive pain [7]. Non-steroidal anti-inflammatory drugs (NSAIDs), other analgesics and corticosteroids are commonly prescribed to aid in pain management. However, it is important to emphasize that prolonged administration of NSAIDs is a major health concern. They do, in fact, promote temporary relief but they can also make the patient more susceptible to the development of serious adverse events such as peptic ulcer disease, acute renal failure, and even myocardial infarction [8]. Non-pharmacological alternatives, on the other hand, are less aggressive in this sense but are still quite limited in terms of regenerative potential [9]. Physical therapy, low impact exercise, weight loss, physical aids and nerve ablation are typical examples of non-pharmacological strategies that may assist in the treatment of OA during its initial stages; however, these may not suffice in more severe and advanced stages, such as grade 4 OA, where surgical intervention procedures may be inevitable [6,9].
These hurdles have motivated medical experts to develop novel alternative methods that are able to target the pathophysiological progression of OA without promoting secondary problems. Such alternatives are widely known as orthobiologics, which have been a subject of much discussion and controversy in the literature, especially when it comes to their application in musculoskeletal regenerative medicine. In short, these biomaterials are derived from biological components that are naturally found in the body, with the ability to enhance the healing process of orthopedic conditions [10].
There are many popular examples given in the literature, such as platelet-rich plasma (PRP), platelet-rich fibrin (PRF) hyaluronic acid (HA), bone marrow aspirate/concentrate (BMA/BMAC) and even adipose tissue [11,12]. These products can have autologous or allogeneic origins and are known to be rich in cellular and molecular components [13]. For decades these components have demonstrated a significant capacity to modulate not only the pathophysiology of OA but many other disease processes as well, providing great optimism in the field of regenerative medicine [13].
Previously, we published the description of two techniques: BMA Matrix [14] and Platelet-Rich Plasma Gel Matrix (PRP-GM) [15]. Both techniques consist in the generation of a rich autologous biological matrix; the first one is obtained via mixture of BMA with HA, and the second one requires mixing PRP, HA and platelet-poor plasma gel. The objective of this narrative review follows the same principle. We propose a treatment alternative for osteoarthritis, focusing on autologous PRP and PRF, two well-known fibrin-rich products, and their association with HA in order to form a rich biological gelmatrix.

2. Methods

Literature was reviewed using PubMed and Google Scholar in order to reveal the regenerative medicine potential of fibrin-rich orthobiologic products. The investigation included a combination of nomenclature such as: “osteoarthritis”, “inflammation”, “orthobiologics”, “fibrin”, “fibrinolytic reactions”, “platelet-rich plasma”, “platelet-rich fibrin” and “hyaluronic acid”. Only full-text articles in English were considered for review.

3. OA Etiopathogenesis

OA progression is driven by the by the intricate interplay of various local, systemic, and external factors, which consequently dictate progression outcome and the patient’s response to treatment [6]. OA is characterized by multiple hallmarks, such as gradual degeneration of articular cartilage, the formation of osteophytes, thickening of the subchondral bone, increased inflammation of the synovium, deterioration of ligaments and menisci, and an overall increase in joint size [3].
The development of OA is a result of a combination of various factors, including genetic predisposition, obesity, traumatic injuries, aging, and the presence of other systemic diseases [16]. It affects the entire joint compartment, and previous research indicates that the degenerative process occurs in two distinct phases. Firstly, in the biosynthetic phase, chondrocytes attempt to repair damaged extracellular matrix (ECM) repeatedly. Subsequently, in the degradative phase, elevated catabolic enzyme activity promotes digestion of the ECM and inhibits the synthesis of new ECM [7]. Continuous biomechanical and biochemical stress causes secondary alterations, resulting in a predominant shift towards catabolic reactions. These biological processes are responsible for cartilage erosion and injury to the subchondral bone and peripheral structures, all of which worsen physical pain and debilitation [17].
To expand further, synoviocytes and chondrocytes affected by OA produce high levels of MMPs (matrix metalloproteinases) such as MMP-1, MMP-3, MMP-9, and MMP-13 [18]. Synoviocytes secrete proteolytic enzymes and pro-inflammatory cytokines, including IL-1β, IL-6, and tumor necrosis factor alpha (TNF-α). These mediators play a role in both the progression of OA and the perception of painful stimuli associated with the condition [19]. Other molecules, such as resistin and osteopontin, are significantly elevated in osteoarthritic synovial tissue, and their increased expression is associated with disease severity [20,21,22]. Although cartilage itself produces most of the catabolic molecules via autocrine and paracrine signaling mechanisms, the synovium has also been reported to produce some chemokines and metalloproteinases that contribute to the degeneration of cartilage [23]. As a result, the breakdown products generated from cartilage degradation, either through biomechanical or biochemical insult, can stimulate the release of collagenase and other hydrolytic enzymes from synovial cells. This process contributes to vascular hyperplasia in the synovial membranes affected by OA [24].
In healthy individuals, articular cartilage is primarily composed of ECM that contains water, collagen, proteoglycans, and a small amount of calcium salt, as well as chondrocytes [25]. The turnover rate of collagen is relatively slow, while the turnover rate of proteoglycan is relatively faster [17]. Chondrocytes are responsible for controlling this process and are responsible for synthesizing molecular components, including proteolytic enzymes, which regulate the breakdown of the ECM in articular cartilage [17]. These cells are often exposed to various sources of noxious stimuli, including polypeptides, cytokines, biomechanical signals, and even fragmented components of the ECM itself [17]. Impaired homeostasis leads to an increase in water content and a decrease in proteoglycan content in the ECM. This results in a weakened collagen network due to decreased synthesis of collagen type 2 and increased breakdown of existing collagen. Additionally, there is an increase in the rate of chondrocyte apoptosis [26]. Ultimately, this paves way for the onset of OA, which initiates when chondrocytes fail to maintain a balance between the synthesis and degradation of ECM components [27].
While macrophages can phagocytize microparticles and cellular debris, the overproduction of these particles can cause significant cell stress, making it harder to dispose of them. These accumulated particles then become mediators of inflammation themselves, stimulating chondrocytes to release more catabolic enzymes [28]. Collagen and proteoglycan breakdown products can also be processed by synovial macrophages, triggering the release of TNFα, IL-1, and IL-6. These molecules can bind to chondrocyte receptors, leading to the further release of MMPs and inhibition of the synthesis of collagen type 2. This sequence of events can exacerbate cartilage degeneration and create a more debilitated microenvironment [29].

4. PRP Versus PRF

4.1. PRP

PRP is obtained via whole blood centrifugation. This orthobiologic product is known to contain a variety of cells and biomolecules with a primary focus on the high concentration of platelets above baseline [30,31,32]. PRP can be processed manually or with the assistance of commercial kits; however, since there are many different protocols in the literature there is a lack of consensus regarding an idealistic preparation of PRP. This also creates variance in content among PRP products and, therefore, different terminologies [33,34,35].
Out of the three platelet granules (alpha, delta and lambda), the α-granules found in PRP are the most abundant [36]. The number of α-granules per thrombocyte is estimated to lie around 50-80, constituting approximately 10% of platelet volume [37]. Platelet granules are known to contain a large number of bioactive molecules which, upon activation, are released and subsequently stimulate the natural healing cascade [33,38]. The dense delta granules carry molecules such as magnesium, calcium, adenosine, serotine and histamine, which stimulate clotting [36]. Lambda granules are often regarded as lysosomes because, much like these cellular organelles, they carry enzymes involved in protein, lipid and carbohydrate degradation. Therefore, they are also responsible for the removal of debris and infectious agents from injured tissue [39]. The α-granule proteins, in turn, are involved in crucial biological events including inflammation, clotting, host defense, cell adhesion and cell growth [36].
A treatment plan with PRP ensures accelerated neovascularization, increasing blood supply and nourishment of nearby cells. This is essential for cellular regeneration and the restoration of damaged tissue. Additionally, PRP can improve other biological events including recruitment, proliferation and differentiation of cells, contributing to the proper healing of complicated wounds and tissue injury [40]. In fact, there are multiple studies in the literature which have long shown the benefits of PRP therapy for many musculoskeletal diseases, especially knee OA. Recent randomized clinical trials (RCT), meta-analyses and systematic reviews [41,42,43,44,45] have yet again shown that when compared with conventional alternatives such as HA and NSAIDs, both leukocyte-poor and leukocyte-rich PRP have superior results. In the majority of the studies found, PRP had a more significant effect regarding improvement of pain and function in symptomatic knee OA with safety and efficacy. Only one of the most recent RCTs [46] (published in November 2022) showed that a single intra-articular injection of leukocyte-poor PRP with HA (Artz or HYAJOINT Plus) is effective and safe for 6 months in knee OA patients. Patients showed significant improvements in visual analogue scale (VAS) pain, Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index, Lequesne index and Single leg Stance (SLS) test at 1, 3 and 6 months post intervention.
There has been much investigation aiming to unveil the regenerative mechanisms of platelet concentrates. The benefits associated with PRP therapy, for example, were long believed to be only a result of the relevant abundance of growth factors and their individual biological roles (Table 2). However, further research showed that PRP also promoted important secondary effects, including inflammatory modulation [30,47,48,49,50], anti-catabolic activity [51], normalization of integral autophagy [52,53], cytokine regulation [54,55,56], and pro-anabolic stimuli [57,58]. More importantly, it is also directly involved in fibrinolytic reactions, which are a key step in the resolution of tissue injury [59]. This is of particular biological value as the fibrinolytic system, as a whole, is necessary for the recruitment of mesenchymal stem cells (MSCs), which play an indispensable role in tissue repair [33]. Lastly, another beneficial effect associated with PRP therapy is mononuclear cell recruitment. Thrombin and platelet factor 4 (PF4) released by platelets promote recruitment of monocytes and their subsequent differentiation into macrophages [60,61,62]. The role of these cells has been much appreciated by researchers due to their plasticity. They have the inherent ability to switch phenotypes (polarization) and also transdifferentiate into other cell types like endothelial cells in order to display additional functions in response to biological cues in the wound microenvironment [63,64,65]. Macrophages express two major phenotypes: M1 and M2. M1 is induced by microbial agents, therefore assuming a more pro-inflammatory role associated with wound debridement. M2 is generally produced by type 2 responses, conveying anti-inflammatory properties characterized by the upregulated expression of IL-4, IL-5, IL-9 and IL-13 [64]. Macrophage polarization is mostly driven by the final stages of wound healing, as M1 macrophages trigger neutrophils apoptosis, initiating clearance [66]. Once neutrophils are phagocyted, pro-inflammatory cytokine production is switched off and macrophages are then allowed to undergo polarization and release TGF-β1. This molecule plays a pivotal role in regulating myofibroblast differentiation for wound contraction, thus allowing resolution of inflammation and initiation of the proliferative phase in healing [59].

4.2. PRF

Furthermore, platelet concentrates are not only appreciated for their capacity to yield enormous quantities of growth factors and proteins. Fibrin is another essential component in such products but it is often misprized and therefore deserves its fair share of credit in tissue repair. PRF, in particular, is a major source of fibrin and is acknowledged as a second generation of platelet concentrates. Although somewhat similar, PRF has a few comparable improvements over the traditional PRP, which has minor drawbacks such as blood handling as well as the addition of anticoagulants [67]. This alternative biomaterial represents a natural fibrin matrix that not only displays immunological and platelet concentrate properties but also holds all the hematological components that are naturally involved in healing and immune function [67]. PRF works like an autologous cicatricial matrix that is simply the result of centrifuged peripheral blood without the addition of any external agents [68]. In reality, this biograft is a fibrin-matrix polymer with a tetra molecular structure, incorporating platelets, leukocytes, cytokines, and even circulating stem cells [69]. The adhesive properties of PRF [70] can convey superior advantages as this material may last longer in target joints, thus sustaining prolonged growth factor delivery and stable cell adhesion and proliferation.
Research indicates that at least in comparison to PRP, PRF could still contribute to the healing process without triggering intense “flare-ups” that can occasionally happen with PRP injections, especially when using leukocyte-rich PRP [7]. PRF offers some versatility in the sense that it can also be easily manipulated used as a membrane, assisting the closure of chronic wounds, or even as a platelet gel in conjunction with other biomaterials such as bone grafts, targeting the improvement of bone tissue repair [71,72,73,74].
Although there are various protocols describing the preparation of platelet concentrates, the preparation of PRF is very simple with minor differences, starting by the exclusion of anticoagulants, which are known suppressors of tissue regeneration [75]. In simple terms, venipuncture is performed and blood is collected into plastic tubes, which may or may not be coated with clot activator (i.e. glass, silica, thrombin) to accelerate coagulation. The tubes are then immediately placed in a centrifuge and only one round of centrifugation is performed, usually at 400 g for 10 minutes [76]. After centrifugation, a heterogeneous mixture is obtained: erythrocytes, which are the densest particles, are separated from the plasma and remain at the bottom layer of the suspension, whilst platelet-poor plasma (PPP) occupies the superior fraction (Figure 1C). The fibrin clot that is formed between the PPP and erythrocytes layers is what makes PRF such an interesting orthobiologic tool. It entraps platelets, leukocytes, and growth factors, thus becoming a natural and autologous bioscaffold (Figure 2) and a rich reservoir of bioactive molecules for tissue regeneration [76,77,78]. PRF can then be easily removed and collected from the tube with a forceps for further applications.
The fundamental mechanism at play is the combination of fibrinogen with circulating thrombin as centrifugation occurs in order to form fibrin and, ultimately, the fibrin clot [67]. Platelet activation and fibrin polymerization are two important events that take place. Platelets are activated immediately upon contact with the wall of the tubes, leading to the formation of the dense fibrin network which gives the PRF clot its typical characteristics [76]. Time is of the essence: when working with PRF, the operator must be able to quickly collect blood and centrifuge it immediately in order to avoid premature coagulation. Ideally, this should be done within 2 minutes and 30 seconds [76]. Any prolongation during this stage causes diffuse fibrin polymerization, making the obtained PRF sample unsuitable for clinical use [76,79]. Despite these observations and “technical complications”, it is interesting to note that an injectable version of PRF (i-PRF) also exists, offering more feasibility in treatment alternatives [75]. Injectable PRF is typically prepared in vacuum tubes with no additives (Figure 1) in order to delay coagulation. This can provide physicians with sufficient time to process the orthobiologic sample as needed and make an intra-articular application. It is worthy to note that PRP alone is known to be a quite diffusible biostimulator, which can sometimes hinder its therapeutic value depending on where it is being injected [80]. Therefore, the association of HA, i-PRF and PRP (power mix) may produce enhanced biological effects, allowing them to remain for an extended amount of time in the target joint.
Clinical studies and other previous investigations have revealed positive effects regarding the administration of PRF either alone or in association with other products for OA of different joints. A recent pilot study [80] comparing leukocyte and platelet-rich fibrin (L-PRF) versus PRP + HA in the treatment of patients affected by unilateral knee degenerative OA revealed that the fibrin counterpart promotes better pain control and longer pain relief in short-and-mid-term.
Recent findings from a double-blind clinical study [81] revealed that the combination of high molecular weight HA with plasma fibrinogen conveys positive effects on knee OA symptoms for all assessed parameters, marked by a significant reduction in OA-associated pain. The fibrin-HA formulations used in this clinical trial (RegenoGel and RegenoGel-OSP) demonstrated significant improvements in VAS scores compared to placebo at three months after the first injection, and sustained for another three months after the second injection with. These results indicate that fibrin and HA conjugates are safe and potentially effective for at least six months in the treatment of knee OA (KOA) symptoms. Indeed, combining HA with fibrin can enhance biological effects. Scanning electron microscopy of HA + fibrin composites shows that this association promotes more robust fibrin polymerization from solid to porous structures [82]. This can further contribute to cell survival, attachment, migration and proliferation [83,84].
In similar fashion, a recent prospective study [85] aimed at evaluating a 36-month survival analysis of conservative treatment using PRP enhanced with i-PRF in 368 knee OA patients. Results showed that the overall survival rate of knees that did not require surgical intervention during the 36-month follow-up was 80.18%, thus being considered satisfactory. This reveals a potentiating property for i-PRF, which in this case was able to enhance regenerative effects upon being combined with PRP.
In cranio-maxillofacial applications PRF has also demonstrated promising results in temporomandibular joint (TMJ) disorders, such as TMJ-OA. A recent RCT [86] assessed the treatment outcomes of intra articular (IA) delivery of i-PRF after arthrocentesis in patients with TMJ-OA. In comparison to the control group (arthrocentesis alone), i-PRF demonstrated superior results in terms of pain reduction and improvement of functional jaw movements. Another similar clinical study [87] evaluated the effects of IA i-PRF treatment in patients suffering from unilateral click due to TMJ disorders. The clicking completely disappeared in 70% of the patients in just 1 week after the first injection, and then in all patients 1 week after second injection. Taken together, evidence indicates PRF’s efficacy in the management of TMJ disorders as well, demonstrating satisfactory results in pain relief and functional gains.
There are many molecular mechanisms underpinning the efficacy of platelet and fibrin rich products, however, particular importance should be given to the fibrinolytic systems, which will be discussed in the subsequent sections of this manuscript.

4.3. Hyaluronic Acid

Hyaluronic acid is an anionic, non-sulfated glycosaminoglycan abundantly found in multiple organ systems [88]. HA is also an essential component of articular cartilage in which it exists as a protective layer surrounding chondrocytes. Furthermore, it acts as a lubricant for tendons and joints, reducing extracellular matrix (ECM) degradation via inhibition of matrix metalloproteinase (MMP) synthesis. Its anti-inflammatory effects attenuate the activity of tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1), two major pro-inflammatory mediators.
HA by itself can be a potent agent in the management of OA, especially of the knee. Its benefits for orthopedic conditions have been well documented in the literature for decades. More recently, systematic reviews have yet again shown that IA applications of HA are safe and cost effective as they reduce pain and improve knee function in comparison to conservative treatments, including NSAIDs, corticosteroids, and analgesics [89,90]. IA-HA is regarded as a minimally invasive interventional strategy and there are no records of major systemic adverse events [91]. This approach has shown beneficial effects in vitro. IA-HA has been shown to not only reduce chondrocyte apoptosis but also increase its proliferation [92]. In humans, it is best to use formulations with medium to high molecular weight (MW) HA in order to closely emulate the conditions and biological properties of HA naturally produced in the body. Also, it is important to use HA derived from biological synthesis, to avoid undesired side effects [93]. HA products with higher molecular weights normally sustain anti-inflammatory effects because they regulate immune cell recruitment. On the other hand, formulations with lower molecular weights have been reported to promote angiogenesis and tissue remodeling in wound healing, however they may also display a more pro-inflammatory effect in specific cell types such, especially chondrocytes [94,95].
Low molecular weight (LMW) HA binds to cell surface receptors less efficiently, therefore promoting weak HA biosynthesis. Medium molecular weight (MMW) HA allows stronger binding, stimulating a higher number of HA receptors, thus enhancing endogenous HA production. It is worthy to note that extremely large molecules present in high molecular weight (HMW) HA products may not always be convenient [96]. These molecules will still bind to HA receptors, however, their large domains can limit the number of free binding sites on the cell surface, which logically implies a less efficient stimulation of HA biosynthesis [96].
The molecular mechanisms of this modality are attributed to the ability of HA to bind to cluster of differentiation 44 (CD44) receptors. This blocks the expression of IL-1β, therefore downregulating the production of MMPs 1, 2, 3, 9, and 13 [97,98,99], bypassing the activity of catabolic enzymes in musculoskeletal structures [100]. After binding to its receptor, HA triggers intracellular signaling pathways associated with proliferation, differentiation, migration and degradation of HA itself [101]. CD44 is the most widely studied HA receptor because it is expressed in nearly all human cell types. Affinity between CD44 and HA is a crucial factor that dictates the potential of HA as a signaling molecule. However, this also depends on HA concentration and MW, as well as glycosylation of extracellular domains and phosphorylation of serine [102]. CD44 can form clusters with HMW HA polymers, allowing interaction with growth factors, ECM proteins, MMPs and cytokines [103]. Another important HA surface receptor is CD168. It is expressed in multiple cells and controls migration by interacting with skeletal proteins, especially in the healing cascade [102].

4.4. The Role of Fibrin in Regeneration

4.4.1. Fibrinolytic Reactions

Platelets contain various factors related to the fibrinolytic system that can either increase or decrease fibrinolytic reactions. The extent of contribution of different hematological components and the role of platelets in the degradation of fibrin are still debated in the scientific community [104]. While many studies have focused solely on platelets, other components such as coagulation factors and the entire fibrinolytic system have also been found to play an important role in efficient tissue repair [59]. In simple terms, fibrinolysis is a complex process that requires the activation of specific plasma proteins to promote the degradation of fibrin [59]. Previous studies have acknowledged the importance of fibrinolytic reactions, suggesting that fibrin degradation products (FDPs) could potentially drive tissue repair, preceding the sequence of events from fibrin deposition and removal all the way to angiogenesis, which is vital for wound healing [105].
When injury occurs, the formation of a clot is essential to protect tissues from blood loss and microbial invasion. However, the clot also serves as a provisional matrix that allows efficient cell migration during repair [106,107]. This clot is made up of an aggregation of platelets embedded in a mesh of cross-linked fibrin fibers resulting from the cleavage of fibrinogen by serine proteases. This reaction triggers the polymerization of fibrin monomers, which is the primary event in the formation of a blood clot [59]. The clot can also act as a storage site for cytokines and growth factors that are released upon degranulation of activated platelets [59,108].
The fibrinolytic system, which is tightly regulated by plasmin, plays an important role in cell migration, regulation of growth factor availability and other protease systems involved in tissue inflammation and regeneration [109,110]. The two major components involved in fibrinolytic reactions are urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1). Both are expressed in mesenchymal stem cells (MSCs), which are specialized cells that are necessary for successful wound healing [109].
Previous studies have suggested that uPAR, in particular, plays a key role in MSC mobilization, similar to what occurs in hematopoietic stem cell (HSC) mobilization. Vallabhaneni and colleagues demonstrated that the administration of granulocyte colony-stimulating factor in uPAR deficient mice resulted in the failure of MSC mobilization [111], emphasizing the supportive role of fibrinolytic systems in stem cell migration. Further research has shown that the glycosylphosphatidylinositol-anchored uPA receptor activates specific intracellular signaling pathways, such as the prosurvival phosphatidylinositol4,5-bisphosphate 3-kinase/Akt and ERK1/2 signaling, and the focal adhesion kinase (FAK), to regulate adhesion, migration, proliferation, and differentiation [112,113].
In the context of wound healing, fibrinolytic factors play a crucial role. Studies on mice have shown that plasminogen deficiency causes a severe delay in wound healing events, suggesting an indispensable role of plasmin in this process [114]. In humans, loss of plasmin also leads to complications in wound healing. Impaired blood flow can significantly stagnate tissue regeneration, which would also explain why these regenerative processes are much more challenging in diabetic patients, for example [115,116]. MSCs are recruited to the wound site to accelerate the healing process [117]; under normal conditions, they express uPA, uPAR, and PAI-1, which are important for wound healing [118]. The proteins uPAR and PAI-1 are regulated by hypoxia inducible factor α (HIF-1α) in MSCs [119], which is beneficial because activating HIF-1α increases the production of FGF-2 and HGF; HIF-2α in turn increases the production of VEGF-A [120]. These molecules collectively aid in wound healing, as shown in Table 2. Additionally, HGF also enhances recruitment of MSCs into the wound site in a synergistic manner [121].
It is important to remember that wounds with poor blood flow and low oxygen levels do significantly hinder the healing cascade. Although MSCs typically inhabit relatively hypoxic tissues (bone marrow), transplanted MSCs may not fare so well in wounds with such adverse conditions, which can limit their healing potential [122]. The way in which MSCs attach to and survive in hypoxic conditions depends on their production of fibrinolytic factors. PAI-1 competes with uPAR and integrins to bind to vitronectin, which results in the inhibition of cell adhesion, migration, and proliferation [123]. However, when PAI-1 interacts with PAs, the affinity of PAI-1 for vitronectin is lost, which allows for cell migration [109]. This process determines whether the MSCs will adhere to a surface or migrate, and it also affects their survival.
Authors’ note: The administration of the autologous “power mix” (PRP + PRF + HA) as shown in Figure 3 may be a viable solution in regenerative medicine for musculoskeletal conditions, as it is cost-effective and low-risk. The fibrin in the mix serves as a natural adhesive matrix that aids in the delivery of growth factors and bioactive molecules to the cells. When combined with additional PRP components, it may enhance the regenerative effects because the fibrin matrix itself has a strong affinity for platelets. This allows platelets to efficiently degranulate and release their contents for an extended amount of time in the local wound microenvironment. This in turn effectively modulates inflammation and recruitment of additional cells, therefore facilitating the progression of tissue repair.

5. Conclusions

Fibrin-rich orthobiologic products such as autologous platelet concentrates have long been studied and appreciated for their positive effects in numerous conditions. The application of PRP and its derivatives, such as PRF, has produced optimistic results in both clinical and laboratory scenarios regarding musculoskeletal disorders, especially OA.
Although PRP and PRF have particularities of their own, they also share essential similarities in principle. The relative abundance of platelets, peripheral blood cells and molecular components in these orthobiologic products provokes many biological events. Examples include inflammatory modulation, enhanced neovascularization, and delivery of pro-anabolic stimuli which regulates recruitment, proliferation and differentiation of cells. Furthermore, the fibrinolytic system has also been demonstrated to have an impact on the recruitment of inflammatory cells and MSCs, as well as regulating proteolytic activity in areas of tissue regeneration, such as bone, cartilage, and muscle. Therefore, it is an important component in musculoskeletal regenerative medicine.
PRP is often regarded as a potent signaling agent, but it is quite diffusible; PRF offers a durable scaffolding effect, favoring cell activity. However, combining HA with fibrin enhances scaffolding properties, as this association promotes more robust fibrin polymerization, aiding cell survival, attachment, migration and proliferation. Therefore, the autologous administration of the “power mix” may prove to be feasible in regenerative medicine, being cost-effective and low-risk.
Despite the growing number of platelet and fibrin-rich derivatives for the treatment of orthopedic diseases, future investigations are still needed in order to further comprehend the factors that contribute to musculoskeletal tissue repair.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Hunter, D.J.; March, L.; Chew, M. Osteoarthritis in 2020 and beyond: A Lancet Commission. The Lancet 2020. [Google Scholar] [CrossRef] [PubMed]
  2. Zhang, Y.; Jordan, J.M. Epidemiology of Osteoarthritis. Clinics in Geriatric Medicine 2010. [Google Scholar] [CrossRef] [PubMed]
  3. Chen, D.; Shen, J.; Zhao, W.; Wang, T.; Han, L.; Hamilton, J.L.; Im, H.J. Osteoarthritis: Toward a Comprehensive Understanding of Pathological Mechanism. Bone Research 2017. [Google Scholar] [CrossRef] [PubMed]
  4. Azzini, G.O.M.; Santos, G.S.; Visoni, S.B.C.; Azzini, V.O.M.; Santos, R.G. dos; Huber, S.C.; Lana, J.F. Metabolic Syndrome and Subchondral Bone Alterations: The Rise of Osteoarthritis – A Review. Journal of Clinical Orthopaedics and Trauma 2020. [Google Scholar] [CrossRef] [PubMed]
  5. Yunus, M.H.M.; Nordin, A.; Kamal, H. Pathophysiological Perspective of Osteoarthritis. Medicina 2020, 56, 614. [Google Scholar] [CrossRef]
  6. Mora, J.C.; Przkora, R.; Cruz-Almeida, Y. Knee Osteoarthritis: Pathophysiology and Current Treatment Modalities. Journal of Pain Research 2018. [Google Scholar] [CrossRef] [PubMed]
  7. Lana, J.F.; Macedo, A.; Ingrao, I.L.G.; Huber, S.C.; Santos, G.S.; Santana, M.H.A. Leukocyte-Rich PRP for Knee Osteoarthritis: Current Concepts. Journal of Clinical Orthopaedics and Trauma 2019. [Google Scholar] [CrossRef] [PubMed]
  8. Marcum, Z.A.; Hanlon, J.T. Recognizing the Risks of Chronic Nonsteroidal Anti-Inflammatory Drug Use in Older Adults. Annals of Long-Term Care 2010. [Google Scholar]
  9. Setti, T.; Arab, M.G.L.; Santos, G.S.; Alkass, N.; Andrade, M.A.P.; Lana, J.F.S.D. The Protective Role of Glutathione in Osteoarthritis. Journal of Clinical Orthopaedics and Trauma 2020. [Google Scholar] [CrossRef]
  10. Santos Duarte Lana, J.F.; Furtado da Fonseca, L.; Mosaner, T.; Tieppo, C.E.; Marques Azzini, G.O.; Ribeiro, L.L.; Setti, T.; Purita, J. Bone Marrow Aspirate Clot: A Feasible Orthobiologic. Journal of Clinical Orthopaedics and Trauma 2020. [Google Scholar] [CrossRef]
  11. Dhillon, M.; Behera, P.; Patel, S.; Shetty, V. Orthobiologics and Platelet Rich Plasma. Indian Journal of Orthopaedics 2014. [Google Scholar] [CrossRef] [PubMed]
  12. Purita, J.; Duarte Lana, J.F.S.; Kolber, M.; Rodrigues, B.L.; Mosaner, T.; Santos, G.S.; Caliari-Oliveira, C.; Huber, S.C. Bone Marrow-Derived Products: A Classification Proposal - Bone Marrow Aspirate, Bone Marrow Aspirate Concentrate or Hybrid? World Journal of Stem Cells 2020. [Google Scholar] [CrossRef] [PubMed]
  13. Huddleston, H.P.; Maheshwer, B.; Wong, S.E.; Chahla, J.; Cole, B.J.; Yanke, A.B. An Update on the Use of Orthobiologics: Use of Biologics for Osteoarthritis. Operative Techniques in Sports Medicine 2020. [Google Scholar] [CrossRef]
  14. Lana, J.F.; da Fonseca, L.F.; Azzini, G.; Santos, G.; Braga, M.; Cardoso Junior, A.M.; Murrell, W.D.; Gobbi, A.; Purita, J.; de Andrade, M.A.P. Bone Marrow Aspirate Matrix: A Convenient Ally in Regenerative Medicine. International Journal of Molecular Sciences 2021. [Google Scholar] [CrossRef]
  15. Godoi, T.T.F.; Rodrigues, B.L.; Huber, S.C.; Santana, M.H.A.; da Fonseca, L.F.; Santos, G.S.; Azzini, G.O.M.; Mosaner, T.; Paulus-Romero, C.; Lana, J.F.S.D. Platelet-Rich Plasma Gel Matrix (PRP-GM): Description of a New Technique. Bioengineering (Basel) 2022, 9, 817. [Google Scholar] [CrossRef]
  16. Wojdasiewicz, P.; Poniatowski, Ł.A.; Szukiewicz, D. The Role of Inflammatory and Anti-Inflammatory Cytokines in the Pathogenesis of Osteoarthritis. Mediators of Inflammation 2014. [Google Scholar] [CrossRef]
  17. Man, G.S.; Mologhianu, G. Osteoarthritis Pathogenesis - a Complex Process That Involves the Entire Joint. Journal of medicine and life 2014. [Google Scholar]
  18. Yuan, G.-H.; Tanaka, M.; Masuko-Hongo, K.; Shibakawa, A.; Kato, T.; Nishioka, K.; Nakamura, H. Characterization of Cells from Pannus-like Tissue over Articular Cartilage of Advanced Osteoarthritis. Osteoarthritis and Cartilage 2004, 12, 38–45. [Google Scholar] [CrossRef]
  19. Sellam, J.; Berenbaum, F. The Role of Synovitis in Pathophysiology and Clinical Symptoms of Osteoarthritis. Nature Reviews Rheumatology 2010. [Google Scholar] [CrossRef]
  20. Lee, J.H.; Ort, T.; Ma, K.; Picha, K.; Carton, J.; Marsters, P.A.; Lohmander, L.S.; Baribaud, F.; Song, X.-Y.R.; Blake, S. Resistin Is Elevated Following Traumatic Joint Injury and Causes Matrix Degradation and Release of Inflammatory Cytokines from Articular Cartilage in Vitro. Osteoarthritis and Cartilage 2009, 17, 613–620. [Google Scholar] [CrossRef]
  21. Presle, N.; Pottie, P.; Dumond, H.; Guillaume, C.; Lapicque, F.; Pallu, S.; Mainard, D.; Netter, P.; Terlain, B. Differential Distribution of Adipokines between Serum and Synovial Fluid in Patients with Osteoarthritis. Contribution of Joint Tissues to Their Articular Production. Osteoarthritis and Cartilage 2006, 14, 690–695. [Google Scholar] [CrossRef]
  22. Hasegawa, M.; Segawa, T.; Maeda, M.; Yoshida, T.; Sudo, A. Thrombin-Cleaved Osteopontin Levels in Synovial Fluid Correlate with Disease Severity of Knee Osteoarthritis. J Rheumatol 2011, 38, 129–134. [Google Scholar] [CrossRef]
  23. Krasnokutsky, S.; Attur, M.; Palmer, G.; Samuels, J.; Abramson, S.B. Current Concepts in the Pathogenesis of Osteoarthritis. Osteoarthritis and Cartilage 2008, 16, S1–S3. [Google Scholar] [CrossRef]
  24. Ashraf, S.; Walsh, D.A. Angiogenesis in Osteoarthritis. Current Opinion in Rheumatology 2008, 20, 573–580. [Google Scholar] [CrossRef]
  25. Goldring, M.B.; Marcu, K.B. Cartilage Homeostasis in Health and Rheumatic Diseases. Arthritis Res Ther 2009, 11, 224. [Google Scholar] [CrossRef]
  26. Buckwalter, J.A.; Mankin, H.J.; Grodzinsky, A.J. Articular Cartilage and Osteoarthritis. Instr Course Lect 2005, 54, 465–480. [Google Scholar]
  27. Heijink, A.; Gomoll, A.H.; Madry, H.; Drobnič, M.; Filardo, G.; Espregueira-Mendes, J.; Van Dijk, C.N. Biomechanical Considerations in the Pathogenesis of Osteoarthritis of the Knee. Knee Surg Sports Traumatol Arthrosc 2012, 20, 423–435. [Google Scholar] [CrossRef]
  28. Wang, M.; Peng, Z.; Vasilev, K.; Ketheesan, N. Investigation of Wear Particles Generated in Human Knee Joints Using Atomic Force Microscopy. Tribol Lett 2013, 51, 161–170. [Google Scholar] [CrossRef]
  29. Stannus, O.; Jones, G.; Cicuttini, F.; Parameswaran, V.; Quinn, S.; Burgess, J.; Ding, C. Circulating Levels of IL-6 and TNF-α Are Associated with Knee Radiographic Osteoarthritis and Knee Cartilage Loss in Older Adults. Osteoarthritis and Cartilage 2010, 18, 1441–1447. [Google Scholar] [CrossRef]
  30. Parrish, W.R.; Roides, B. Musculoskeletal Regeneration. Musculoskeletal Regeneration 2017. [Google Scholar] [CrossRef]
  31. Marx, R.E. Platelet-Rich Plasma: Evidence to Support Its Use. Journal of Oral and Maxillofacial Surgery 2004. [Google Scholar] [CrossRef]
  32. Rui, S.; Yuan, Y.; Du, C.; Song, P.; Chen, Y.; Wang, H.; Fan, Y.; Armstrong, D.G.; Deng, W.; Li, L. Comparison and Investigation of Exosomes Derived from Platelet-Rich Plasma Activated by Different Agonists. Cell Transplant 2021, 30, 9636897211017832. [Google Scholar] [CrossRef]
  33. dos Santos, R.G.; Santos, G.S.; Alkass, N.; Chiesa, T.L.; Azzini, G.O.; da Fonseca, L.F.; dos Santos, A.F.; Rodrigues, B.L.; Mosaner, T.; Lana, J.F. The Regenerative Mechanisms of Platelet-Rich Plasma: A Review. Cytokine 2021. [Google Scholar] [CrossRef]
  34. Dohan Ehrenfest, D.M.; Andia, I.; Zumstein, M.A.; Zhang, C.Q.; Pinto, N.R.; Bielecki, T. Classification of Platelet Concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for Topical and Infiltrative Use in Orthopedic and Sports Medicine: Current Consensus, Clinical Implications and Perspectives. Muscles, Ligaments and Tendons Journal 2014. [Google Scholar] [CrossRef]
  35. Dohan Ehrenfest, D.M.; Rasmusson, L.; Albrektsson, T. Classification of Platelet Concentrates: From Pure Platelet-Rich Plasma (P-PRP) to Leucocyte- and Platelet-Rich Fibrin (L-PRF). Trends Biotechnol 2009, 27, 158–167. [Google Scholar] [CrossRef]
  36. Pavlovic, V.; Ciric, M.; Jovanovic, V.; Stojanovic, P. Platelet Rich Plasma: A Short Overview of Certain Bioactive Components. Open Medicine (Poland) 2016. [Google Scholar] [CrossRef]
  37. Maynard, D.M.; Heijnen, H.F.G.; Horne, M.K.; White, J.G.; Gahl, W.A. Proteomic Analysis of Platelet Alpha-Granules Using Mass Spectrometry. J Thromb Haemost 2007, 5, 1945–1955. [Google Scholar] [CrossRef]
  38. Parrish, W.R.; Roides, B.; Hwang, J.; Mafilios, M.; Story, B.; Bhattacharyya, S. Normal Platelet Function in Platelet Concentrates Requires Non-Platelet Cells: A Comparative in Vitro Evaluation of Leucocyte-Rich (Type 1a) and Leucocyte-Poor (Type 3b) Platelet Concentrates. BMJ Open Sport Exerc Med 2016, 2, e000071. [Google Scholar] [CrossRef]
  39. Boswell, S.G.; Cole, B.J.; Sundman, E.A.; Karas, V.; Fortier, L.A. Platelet-Rich Plasma: A Milieu of Bioactive Factors. Arthroscopy - Journal of Arthroscopic and Related Surgery 2012. [Google Scholar] [CrossRef]
  40. Foster, T.E.; Puskas, B.L.; Mandelbaum, B.R.; Gerhardt, M.B.; Rodeo, S.A. Platelet-Rich Plasma: From Basic Science to Clinical Applications. American Journal of Sports Medicine 2009. [Google Scholar] [CrossRef]
  41. Meheux, C.J.; McCulloch, P.C.; Lintner, D.M.; Varner, K.E.; Harris, J.D. Efficacy of Intra-Articular Platelet-Rich Plasma Injections in Knee Osteoarthritis: A Systematic Review. Arthroscopy 2016, 32, 495–505. [Google Scholar] [CrossRef]
  42. Belk, J.W.; Kraeutler, M.J.; Houck, D.A.; Goodrich, J.A.; Dragoo, J.L.; McCarty, E.C. Platelet-Rich Plasma Versus Hyaluronic Acid for Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Sports Med 2021, 49, 249–260. [Google Scholar] [CrossRef]
  43. Hong, M.; Cheng, C.; Sun, X.; Yan, Y.; Zhang, Q.; Wang, W.; Guo, W. Efficacy and Safety of Intra-Articular Platelet-Rich Plasma in Osteoarthritis Knee: A Systematic Review and Meta-Analysis. Biomed Res Int 2021, 2021, 2191926. [Google Scholar] [CrossRef]
  44. Park, Y.-B.; Kim, J.-H.; Ha, C.-W.; Lee, D.-H. Clinical Efficacy of Platelet-Rich Plasma Injection and Its Association With Growth Factors in the Treatment of Mild to Moderate Knee Osteoarthritis: A Randomized Double-Blind Controlled Clinical Trial As Compared With Hyaluronic Acid. Am J Sports Med 2021, 49, 487–496. [Google Scholar] [CrossRef]
  45. Nie, L.-Y.; Zhao, K.; Ruan, J.; Xue, J. Effectiveness of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Clinical Trials. Orthop J Sports Med 2021, 9, 2325967120973284. [Google Scholar] [CrossRef]
  46. Huang, H.-Y.; Hsu, C.-W.; Lin, G.-C.; Lin, H.-S.; Chou, Y.-J.; Liou, I.-H.; Sun, S.-F. Comparing Efficacy of a Single Intraarticular Injection of Platelet-Rich Plasma (PRP) Combined with Different Hyaluronans for Knee Osteoarthritis: A Randomized-Controlled Clinical Trial. BMC Musculoskelet Disord 2022, 23, 954. [Google Scholar] [CrossRef]
  47. Xie, X.; Wang, Y.; Zhao, C.; Guo, S.; Liu, S.; Jia, W.; Tuan, R.S.; Zhang, C. Comparative Evaluation of MSCs from Bone Marrow and Adipose Tissue Seeded in PRP-Derived Scaffold for Cartilage Regeneration. Biomaterials 2012. [Google Scholar] [CrossRef]
  48. Van Buul, G.M.; Koevoet, W.L.M.; Kops, N.; Bos, P.K.; Verhaar, J.A.N.; Weinans, H.; Bernsen, M.R.; Van Osch, G.J.V.M. Platelet-Rich Plasma Releasate Inhibits Inflammatory Processes in Osteoarthritic Chondrocytes. American Journal of Sports Medicine 2011. [Google Scholar] [CrossRef]
  49. Giannopoulou, M.; Dai, C.; Tan, X.; Wen, X.; Michalopoulos, G.K.; Liu, Y. Hepatocyte Growth Factor Exerts Its Anti-Inflammatory Action by Disrupting Nuclear Factor-ΚB Signaling. American Journal of Pathology 2008. [Google Scholar] [CrossRef]
  50. Marathe, A.; Patel, S.J.; Song, B.; Sliepka, J.M.; Shybut, T.S.; Lee, B.H.; Jayaram, P. Double-Spin Leukocyte-Rich Platelet-Rich Plasma Is Predominantly Lymphocyte Rich With Notable Concentrations of Other White Blood Cell Subtypes. Arthrosc Sports Med Rehabil 2022, 4, e335–e341. [Google Scholar] [CrossRef]
  51. Kennedy, M.I.; Whitney, K.; Evans, T.; LaPrade, R.F. Platelet-Rich Plasma and Cartilage Repair. Current Reviews in Musculoskeletal Medicine 2018. [Google Scholar] [CrossRef]
  52. Moussa, M.; Lajeunesse, D.; Hilal, G.; El Atat, O.; Haykal, G.; Serhal, R.; Chalhoub, A.; Khalil, C.; Alaaeddine, N. Platelet Rich Plasma (PRP) Induces Chondroprotection via Increasing Autophagy, Anti-Inflammatory Markers, and Decreasing Apoptosis in Human Osteoarthritic Cartilage. Experimental Cell Research 2017. [Google Scholar] [CrossRef]
  53. García-Prat, L.; Martínez-Vicente, M.; Perdiguero, E.; Ortet, L.; Rodríguez-Ubreva, J.; Rebollo, E.; Ruiz-Bonilla, V.; Gutarra, S.; Ballestar, E.; Serrano, A.L.; et al. Autophagy Maintains Stemness by Preventing Senescence. Nature 2016. [Google Scholar] [CrossRef]
  54. Saxena, A.; Khosraviani, S.; Noel, S.; Mohan, D.; Donner, T.; Hamad, A.R.A. Interleukin-10 Paradox: A Potent Immunoregulatory Cytokine That Has Been Difficult to Harness for Immunotherapy. Cytokine 2015. [Google Scholar] [CrossRef]
  55. Zhang, J.M.; An, J. Cytokines, Inflammation, and Pain. International Anesthesiology Clinics 2007. [Google Scholar] [CrossRef]
  56. Kendall, R.T.; Feghali-Bostwick, C.A. Fibroblasts in Fibrosis: Novel Roles and Mediators. Frontiers in Pharmacology 2014. [Google Scholar] [CrossRef]
  57. Werner, S.; Grose, R. Regulation of Wound Healing by Growth Factors and Cytokines. Physiological Reviews 2003. [Google Scholar] [CrossRef]
  58. Cavallo, C.; Filardo, G.; Mariani, E.; Kon, E.; Marcacci, M.; Pereira Ruiz, M.T.; Facchini, A.; Grigolo, B. Comparison of Platelet-Rich Plasma Formulations for Cartilage Healing: An in Vitro Study. Journal of Bone and Joint Surgery - Series A 2014. [Google Scholar] [CrossRef]
  59. Opneja, A.; Kapoor, S.; Stavrou, E.X. Contribution of Platelets, the Coagulation and Fibrinolytic Systems to Cutaneous Wound Healing. Thrombosis Research 2019. [Google Scholar] [CrossRef]
  60. Von Hundelshausen, P.; Koenen, R.R.; Sack, M.; Mause, S.F.; Adriaens, W.; Proudfoot, A.E.I.; Hackeng, T.M.; Weber, C. Heterophilic Interactions of Platelet Factor 4 and RANTES Promote Monocyte Arrest on Endothelium. Blood 2005. [Google Scholar] [CrossRef]
  61. Xia, C.Q.; Kao, K.J. Effect of CXC Chemokine Platelet Factor 4 on Differentiation and Function of Monocyte-Derived Dendritic Cells. International Immunology 2003. [Google Scholar] [CrossRef]
  62. Scheuerer, B.; Ernst, M.; Dürrbaum-Landmann, I.; Fleischer, J.; Grage-Griebenow, E.; Brandt, E.; Flad, H.D.; Petersen, F. The CXC-Chemokine Platelet Factor 4 Promotes Monocyte Survival and Induces Monocyte Differentiation into Macrophages. Blood 2000. [Google Scholar] [CrossRef]
  63. Gratchev, A.; Kzhyshkowska, J.; Köthe, K.; Muller-Molinet, I.; Kannookadan, S.; Utikal, J.; Goerdt, S. Mφ1 and Mφ2 Can Be Re-Polarized by Th2 or Th1 Cytokines, Respectively, and Respond to Exogenous Danger Signals. Immunobiology 2006. [Google Scholar] [CrossRef]
  64. Das, A.; Sinha, M.; Datta, S.; Abas, M.; Chaffee, S.; Sen, C.K.; Roy, S. Monocyte and Macrophage Plasticity in Tissue Repair and Regeneration. American Journal of Pathology 2015. [Google Scholar] [CrossRef]
  65. Lana, J.F.; Huber, S.C.; Purita, J.; Tambeli, C.H.; Santos, G.S.; Paulus, C.; Annichino-Bizzacchi, J.M. Leukocyte-Rich PRP versus Leukocyte-Poor PRP - The Role of Monocyte/Macrophage Function in the Healing Cascade. Journal of Clinical Orthopaedics and Trauma 2019. [Google Scholar] [CrossRef]
  66. Meszaros, A.J.; Reichner, J.S.; Albina, J.E. Macrophage-Induced Neutrophil Apoptosis. The Journal of Immunology 2000. [Google Scholar] [CrossRef]
  67. Saluja, H.; Dehane, V.; Mahindra, U. Platelet-Rich Fibrin: A Second Generation Platelet Concentrate and a New Friend of Oral and Maxillofacial Surgeons. Ann Maxillofac Surg 2011, 1, 53–57. [Google Scholar] [CrossRef]
  68. Dohan, D.M.; Choukroun, J.; Diss, A.; Dohan, S.L.; Dohan, A.J.J.; Mouhyi, J.; Gogly, B. Platelet-Rich Fibrin (PRF): A Second-Generation Platelet Concentrate. Part I: Technological Concepts and Evolution. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology 2006. [Google Scholar] [CrossRef]
  69. Choukroun, J.; Diss, A.; Simonpieri, A.; Girard, M.-O.; Schoeffler, C.; Dohan, S.L.; Dohan, A.J.J.; Mouhyi, J.; Dohan, D.M. Platelet-Rich Fibrin (PRF): A Second-Generation Platelet Concentrate. Part IV: Clinical Effects on Tissue Healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006, 101, e56–e60. [Google Scholar] [CrossRef]
  70. Kardos, D.; Hornyák, I.; Simon, M.; Hinsenkamp, A.; Marschall, B.; Várdai, R.; Kállay-Menyhárd, A.; Pinke, B.; Mészáros, L.; Kuten, O.; et al. Biological and Mechanical Properties of Platelet-Rich Fibrin Membranes after Thermal Manipulation and Preparation in a Single-Syringe Closed System. Int J Mol Sci 2018, 19, 3433. [Google Scholar] [CrossRef]
  71. Sunitha Raja, V.; Munirathnam Naidu, E. Platelet-Rich Fibrin: Evolution of a Second-Generation Platelet Concentrate. Indian J Dent Res 2008, 19, 42–46. [Google Scholar] [CrossRef] [PubMed]
  72. Bilgen, F.; Ural, A.; Bekerecioglu, M. Platelet-Rich Fibrin: An Effective Chronic Wound Healing Accelerator. J Tissue Viability 2021, 30, 616–620. [Google Scholar] [CrossRef]
  73. Desai, C.B.; Mahindra, U.R.; Kini, Y.K.; Bakshi, M.K. Use of Platelet-Rich Fibrin over Skin Wounds: Modified Secondary Intention Healing. J Cutan Aesthet Surg 2013, 6, 35–37. [Google Scholar] [CrossRef]
  74. Cortese, A.; Pantaleo, G.; Borri, A.; Caggiano, M.; Amato, M. Platelet-Rich Fibrin (PRF) in Implant Dentistry in Combination with New Bone Regenerative Technique in Elderly Patients. International Journal of Surgery Case Reports 2016, 28, 52–56. [Google Scholar] [CrossRef]
  75. Miron, R.J.; Fujioka-Kobayashi, M.; Hernandez, M.; Kandalam, U.; Zhang, Y.; Ghanaati, S.; Choukroun, J. Injectable Platelet Rich Fibrin (i-PRF): Opportunities in Regenerative Dentistry? Clin Oral Invest 2017, 21, 2619–2627. [Google Scholar] [CrossRef]
  76. Pavlovic, V.; Ciric, M.; Jovanovic, V.; Trandafilovic, M.; Stojanovic, P. Platelet-Rich Fibrin: Basics of Biological Actions and Protocol Modifications. Open Med (Wars) 2021, 16, 446–454. [Google Scholar] [CrossRef] [PubMed]
  77. Kang, Y.-H.; Jeon, S.H.; Park, J.-Y.; Chung, J.-H.; Choung, Y.-H.; Choung, H.-W.; Kim, E.-S.; Choung, P.-H. Platelet-Rich Fibrin Is a Bioscaffold and Reservoir of Growth Factors for Tissue Regeneration. Tissue Eng Part A 2011, 17, 349–359. [Google Scholar] [CrossRef]
  78. Bielecki, T.; Ehrenfest, D.M.D.; Everts, P.A.; Wiczkowski, A. The Role of Leukocytes from L-PRP / L-PRF in Wound Healing and Immune Defense : New Perspectives. 2012, 1153–1162.
  79. Miron, R.J.; Bishara, M.; Choukroun, J. Basics of Platelet-Rich Fibrin Therapy. Dent Today 2017, 36, 74–76. [Google Scholar]
  80. Nicola, V.D. L-PRF in Osteoarthritis Treatment: Results of a Pilot Study. J Regen Biol Med 2020. [Google Scholar] [CrossRef]
  81. Kandel, L.; Agar, G.; Elkayam, O.; Sharipov, A.; Slevin, O.; Rivkin, G.; Dahan, M.; Aloush, V.; Pyeser, A.B.; Brin, Y.; et al. A Novel Approach for Knee Osteoarthritis Using High Molecular Weight Hyaluronic Acid Conjugated to Plasma Fibrinogen – Interim Findings of a Double-Blind Clinical Study. Heliyon 2020, 6, e04475. [Google Scholar] [CrossRef]
  82. Jang, J.D.; Moon, Y.S.; Kim, Y.S.; Choi, N.Y.; Mok, H.S.; Kim, Y.J.; Shetty, A.A.; Kim, S.J. Novel Repair Technique for Articular Cartilage Defect Using a Fibrin and Hyaluronic Acid Mixture. Tissue Engineering and Regenerative Medicine 2013. [Google Scholar] [CrossRef]
  83. Shoji, T.; Nakasa, T.; Yoshizuka, M.; Yamasaki, T.; Yasunaga, Y.; Adachi, N.; Ochi, M. Comparison of Fibrin Clots Derived from Peripheral Blood and Bone Marrow. Connective Tissue Research 2017. [Google Scholar] [CrossRef] [PubMed]
  84. Lim, Z.X.H.; Rai, B.; Tan, T.C.; Ramruttun, A.K.; Hui, J.H.; Nurcombe, V.; Teoh, S.H.; Cool, S.M. Autologous Bone Marrow Clot as an Alternative to Autograft for Bone Defect Healing. Bone and Joint Research 2019. [Google Scholar] [CrossRef] [PubMed]
  85. Cheeva-akrapan, V.; Turajane, T.; Cheeva-akrapan, V.; Turajane, T. The 36-Month Survival Analysis of Conservative Treatment Using Platelet-Rich Plasma Enhanced With Injectable Platelet-Rich Fibrin in Patients With Knee Osteoarthritis. Cureus 2023, 15. [Google Scholar] [CrossRef] [PubMed]
  86. Işık, G. Application of Injectable Platelet-Rich Fibrin for the Treatment of Temporomandibular Joint Osteoarthritis: A Randomized Controlled Clinical Trial; clinicaltrials.gov, 2021.
  87. Manafikhi, M.; Ataya, J.; Heshmeh, O. Evaluation of the Efficacy of Platelet Rich Fibrin (I-PRF) Intra-Articular Injections in the Management of Internal Derangements of Temporomandibular Joints – a Controlled Preliminary Prospective Clinical Study. BMC Musculoskelet Disord 2022, 23, 454. [Google Scholar] [CrossRef]
  88. Lisignoli, G.; Cristino, S.; Piacentini, A.; Cavallo, C.; Caplan, A.I.; Facchini, A. Hyaluronan-Based Polymer Scaffold Modulates the Expression of Inflammatory and Degradative Factors in Mesenchymal Stem Cells: Involvement of Cd44 and Cd54. Journal of Cellular Physiology 2006. [Google Scholar] [CrossRef] [PubMed]
  89. Altman, R.; Hackel, J.; Niazi, F.; Shaw, P.; Nicholls, M. Efficacy and Safety of Repeated Courses of Hyaluronic Acid Injections for Knee Osteoarthritis: A Systematic Review. Semin Arthritis Rheum 2018, 48, 168–175. [Google Scholar] [CrossRef] [PubMed]
  90. Mordin, M.; Parrish, W.; Masaquel, C.; Bisson, B.; Copley-Merriman, C. Intra-Articular Hyaluronic Acid for Osteoarthritis of the Knee in the United States: A Systematic Review of Economic Evaluations. Clin Med Insights Arthritis Musculoskelet Disord 2021, 14, 11795441211047284. [Google Scholar] [CrossRef]
  91. Bruyère, O.; Cooper, C.; Pelletier, J.P.; Branco, J.; Luisa Brandi, M.; Guillemin, F.; Hochberg, M.C.; Kanis, J.A.; Kvien, T.K.; Martel-Pelletier, J.; et al. An Algorithm Recommendation for the Management of Knee Osteoarthritis in Europe and Internationally: A Report from a Task Force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism 2014, 44, 253–263. [Google Scholar] [CrossRef]
  92. Brun, P.; Zavan, B.; Vindigni, V.; Schiavinato, A.; Pozzuoli, A.; Iacobellis, C.; Abatangelo, G. In Vitro Response of Osteoarthritic Chondrocytes and Fibroblast-like Synoviocytes to a 500-730 KDa Hyaluronan Amide Derivative. Journal of Biomedical Materials Research Part B: Applied Biomaterials 2012, 100B, 2073–2081. [Google Scholar] [CrossRef]
  93. Kruel, A.V.S.; Ribeiro, L.L.; Gusmão, P.D.; Huber, S.C.; Lana, J.F.S.D. Orthobiologics in the Treatment of Hip Disorders. World J Stem Cells 2021, 13, 304–316. [Google Scholar] [CrossRef] [PubMed]
  94. Campo, G.M.; Avenoso, A.; Campo, S.; D’Ascola, A.; Traina, P.; Rugolo, C.A.; Calatroni, A. Differential Effect of Molecular Mass Hyaluronan on Lipopolysaccharide-Induced Damage in Chondrocytes. Innate Immun 2010, 16, 48–63. [Google Scholar] [CrossRef] [PubMed]
  95. Day, A.J.; de la Motte, C.A. Hyaluronan Cross-Linking: A Protective Mechanism in Inflammation? Trends Immunol 2005, 26, 637–643. [Google Scholar] [CrossRef] [PubMed]
  96. Maheu, E.; Rannou, F.; Reginster, J.Y. Efficacy and Safety of Hyaluronic Acid in the Management of Osteoarthritis: Evidence from Real-Life Setting Trials and Surveys. Seminars in Arthritis and Rheumatism 2016. [Google Scholar] [CrossRef] [PubMed]
  97. Julovi, S.M.; Yasuda, T.; Shimizu, M.; Hiramitsu, T.; Nakamura, T. Inhibition of Interleukin-1β-Stimulated Production of Matrix Metalloproteinases by Hyaluronan via CD44 in Human Articular Cartilage. Arthritis and Rheumatism 2004, 50, 516–525. [Google Scholar] [CrossRef]
  98. Kalaci, A.; Yilmaz, R.H.; Aslan, B.; Sög̈üt, S.; Yanat, A.N.; Uz, E. Effects of Hyaluronan on Nitric Oxide Levels and Superoxide Dismutase Activities in Synovial Fluid in Knee Osteoarthritis. Clinical Rheumatology 2007, 26, 1306–1311. [Google Scholar] [CrossRef]
  99. Karna, E.; Miltyk, W.; Surażyński, A.; Pałka, J.A. Protective Effect of Hyaluronic Acid on Interleukin-1-Induced Deregulation of Βeta 1 -Integrin and Insulin-like Growth Factor-I Receptor Signaling and Collagen Biosynthesis in Cultured Human Chondrocytes. Molecular and Cellular Biochemistry 2008, 308, 57–64. [Google Scholar] [CrossRef]
  100. Abate, M.; Pelotti, P.; De Amicis, D.; Di Iorio, A.; Galletti, S.; Salini, V. Viscosupplementation with Hyaluronic Acid in Hip Osteoarthritis (a Review). Upsala Journal of Medical Sciences 2008, 113, 261–278. [Google Scholar] [CrossRef]
  101. Dicker, K.T.; Gurski, L.A.; Pradhan-Bhatt, S.; Witt, R.L.; Farach-Carson, M.C.; Jia, X. Hyaluronan: A Simple Polysaccharide with Diverse Biological Functions. Acta Biomater 2014, 10, 1558–1570. [Google Scholar] [CrossRef]
  102. Abatangelo, G.; Vindigni, V.; Avruscio, G.; Pandis, L.; Brun, P. Hyaluronic Acid: Redefining Its Role. Cells 2020, 9, 1743. [Google Scholar] [CrossRef]
  103. Vigetti, D.; Karousou, E.; Viola, M.; Deleonibus, S.; De Luca, G.; Passi, A. Hyaluronan: Biosynthesis and Signaling. Biochim Biophys Acta 2014, 1840, 2452–2459. [Google Scholar] [CrossRef] [PubMed]
  104. Panes, O.; Padilla, O.; Matus, V.; Sez, C.G.; Berkovits, A.; Pereira, J.; Mezzano, D. Clot Lysis Time in Platelet-Rich Plasma: Method Assessment, Comparison with Assays in Platelet-Free and Platelet-Poor Plasmas, and Response to Tranexamic Acid. Platelets 2012. [Google Scholar] [CrossRef] [PubMed]
  105. Thompson, W.D.; Harvey, J.A.; Kazmi, M.A.; Stout, A.J. Fibrinolysis and Angiogenesis in Wound Healing. The Journal of Pathology 1991. [Google Scholar] [CrossRef] [PubMed]
  106. Laurens, N.; Koolwijk, P.; de Maat, M.P. Fibrin Structure and Wound Healing. Journal of thrombosis and haemostasis : JTH 2006.
  107. Mullarky, I.K.; Szaba, F.M.; Berggren, K.N.; Parent, M.A.; Kummer, L.W.; Chen, W.; Johnson, L.L.; Smiley, S.T. Infection-Stimulated Fibrin Deposition Controls Hemorrhage and Limits Hepatic Bacterial Growth during Listeriosis. Infection and Immunity 2005. [Google Scholar] [CrossRef] [PubMed]
  108. Dohan Ehrenfest, D.M.; Pinto, N.R.; Pereda, A.; Jiménez, P.; Corso, M.D.; Kang, B.-S.; Nally, M.; Lanata, N.; Wang, H.-L.; Quirynen, M. The Impact of the Centrifuge Characteristics and Centrifugation Protocols on the Cells, Growth Factors, and Fibrin Architecture of a Leukocyte- and Platelet-Rich Fibrin (L-PRF) Clot and Membrane. Platelets 2018, 29, 171–184. [Google Scholar] [CrossRef] [PubMed]
  109. Heissig, B.; Dhahri, D.; Eiamboonsert, S.; Salama, Y.; Shimazu, H.; Munakata, S.; Hattori, K. Role of Mesenchymal Stem Cell-Derived Fibrinolytic Factor in Tissue Regeneration and Cancer Progression. Cellular and Molecular Life Sciences 2015. [Google Scholar] [CrossRef] [PubMed]
  110. Sinclair And, R.D.; Ryan, T.J. PROTEOLYTIC ENZYMES IN WOUND HEALING: THE ROLE OF ENZYMATIC DEBRIDEMENT. Australasian Journal of Dermatology 1994. [Google Scholar] [CrossRef]
  111. Vallabhaneni, K.C.; Tkachuk, S.; Kiyan, Y.; Shushakova, N.; Haller, H.; Dumler, I.; Eden, G. Urokinase Receptor Mediates Mobilization, Migration, and Differentiation of Mesenchymal Stem Cells. Cardiovascular Research 2011. [Google Scholar] [CrossRef]
  112. Syrovets, T.; Lunov, O.; Simmet, T. Plasmin as a Proinflammatory Cell Activator. Journal of Leukocyte Biology 2012. [Google Scholar] [CrossRef]
  113. Gaestel, M.; Kotlyarov, A.; Kracht, M. Targeting Innate Immunity Protein Kinase Signalling in Inflammation. Nature Reviews Drug Discovery 2009. [Google Scholar] [CrossRef]
  114. Rømer, J.; Bugge, T.; Pyke, C.; Lund, L.R.; Flick, M.J.; Degen, J.L.; Danø, K. Impaired Wound Healing in Mice with a Disrupted Plasminogen Gene. Fibrinolysis 1996. [Google Scholar] [CrossRef] [PubMed]
  115. Fadini, G.P.; Albiero, M.; De Kreutzenberg, S.V.; Boscaro, E.; Cappellari, R.; Marescotti, M.; Poncina, N.; Agostini, C.; Avogaro, A. Diabetes Impairs Stem Cell and Proangiogenic Cell Mobilization in Humans. Diabetes Care 2013. [Google Scholar] [CrossRef] [PubMed]
  116. Schäffer, M.; Witte, M.; Becker, H.D. Models to Study Ischemia in Chronic Wounds. The International Journal of Lower Extremity Wounds 2002. [Google Scholar] [CrossRef] [PubMed]
  117. Basiouny, H.S.; Salama, N.M.; El Maadawi, Z.M.; Farag, E.A. Effect of Bone Marrow Derived Mesenchymal Stem Cells on Healing of Induced Full-Thickness Skin Wounds in Albino Rat. International Journal of Stem Cells 2013. [Google Scholar] [CrossRef] [PubMed]
  118. Copland, I.B.; Lord-Dufour, S.; Cuerquis, J.; Coutu, D.L.; Annabi, B.; Wang, E.; Galipeau, J. Improved Autograft Survival of Mesenchymal Stromal Cells by Plasminogen Activator Inhibitor 1 Inhibition. Stem Cells 2009. [Google Scholar] [CrossRef] [PubMed]
  119. Lin, M.T.; Kuo, I.H.; Chang, C.C.; Chu, C.Y.; Chen, H.Y.; Lin, B.R.; Sureshbabu, M.; Shih, H.J.; Kuo, M.L. Involvement of Hypoxia-Inducing Factor-1α-Dependent Plasminogen Activator Inhibitor-1 up-Regulation in Cyr61/CCN1-Induced Gastric Cancer Cell Invasion. Journal of Biological Chemistry 2008. [Google Scholar] [CrossRef] [PubMed]
  120. Tamama, K.; Kawasaki, H.; Kerpedjieva, S.S.; Guan, J.; Ganju, R.K.; Sen, C.K. Differential Roles of Hypoxia Inducible Factor Subunits in Multipotential Stromal Cells under Hypoxic Condition. Journal of Cellular Biochemistry 2011. [Google Scholar] [CrossRef]
  121. Neuss, S.; Becher, E.; Wöltje, M.; Tietze, L.; Jahnen-Dechent, W. Functional Expression of HGF and HGF Receptor/c-Met in Adult Human Mesenchymal Stem Cells Suggests a Role in Cell Mobilization, Tissue Repair, and Wound Healing. STEM CELLS 2004. [Google Scholar] [CrossRef]
  122. Lane, S.W.; Williams, D.A.; Watt, F.M. Modulating the Stem Cell Niche for Tissue Regeneration. Nature Biotechnology 2014. [Google Scholar] [CrossRef]
  123. Zhong, J.; Yang, H.C.; Kon, V.; Fogo, A.B.; Lawrence, D.A.; Ma, J. Vitronectin-Binding PAI-1 Protects against the Development of Cardiac Fibrosis through Interaction with Fibroblasts. Laboratory Investigation 2014. [Google Scholar] [CrossRef]
Preprints 75868 g001
Figure 1. – i-PRF preparation. (A) vacuum-extraction blood specimen collection; (B) centrifugation; (C) i-PRF aspiration.
Figure 1. – i-PRF preparation. (A) vacuum-extraction blood specimen collection; (B) centrifugation; (C) i-PRF aspiration.
Preprints 75868 g001
Preprints 75868 g002
Figure 2. – Fibrin clot matrix.
Figure 2. – Fibrin clot matrix.
Preprints 75868 g002
Preprints 75868 g003
Figure 3. – Power Mix. Power-mix (PRF-PRP-HA matrix) therapy versus conventional analgesics.
Figure 3. – Power Mix. Power-mix (PRF-PRP-HA matrix) therapy versus conventional analgesics.
Preprints 75868 g003
Table 1. Osteoarthritis classification based on the Kellgren-Lawrence scale.
Table 1. Osteoarthritis classification based on the Kellgren-Lawrence scale.
Osteoarthritis Grade Observation
Grade 0 (normal) No radiological findings
Grade I (doubtful) Possible signs of osteophytic lipping and narrowing of joint space
Grade II (mild) Definite osteophytes and possible joint space narrowing
Grade III (moderate) Definite joint space narrowing and multiple osteophytes
Grade IV (severe) Large osteophytes, prominent demarcation of narrowed joint space, severe sclerosis and expressive deformity of bone contour
Table 2. Growth factors in PRP.
Table 2. Growth factors in PRP.
Name Abbreviation Biological Role
Fibroblast growth factor FGF Regulates cell proliferation, survival, migration, and differentiation.
Vascular endothelial growth factor VEGF Stimulates angiogenesis, macrophage and neutrophil chemotaxis, migration and mitosis of endothelial cells, and increases permeability of blood vessels.
Insulin-like growth factor IGF Regulates cell growth and differentiation, stimulates collagen synthesis and recruits cells from bone, endothelium, epithelium and other tissues.
Transforming growth factor-β TGF-β Boosts production of collagen type 1, stimulates angionesis and chemotaxis of immune cells, inhibits osteoclast formation and bone resorption
Hepatocyte growth factor HGF Secreted by mesenchymal cells, HGF stimulates mitogenesis, cell motility, and matrix invasion.
Platelet-derived growth factor PDGF Increases collagen expression, bone cell proliferation, chemotaxis and proliferation of fibroblasts, and macrophage activation.
Epidermal growth factor EGF Stimulates proliferation and differentiation of epithelial cells, promotes secretion of cytokines by mesenchymal and epithelial cells.
Insulin-like growth factor-1 IGF-1 Plays a key role in cell growth and healing via anabolic effects.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated